Unlocking the Potential of Platform Chemicals in Renewable Energy

There are two ways to make money in bio-based chemicals, and they are almost opposites. One is to make a molecule identical to the petrochemical it replaces and win on cost. The other is to make a molecule petroleum cannot easily make at all and win on performance. The first is a bet on the oil price wearing a green label. The second is where the potential of platform chemicals is actually unlocked, because its value does not depend on where crude trades. Most investor attention, and most disappointment, has gone to the first. The durable returns are in the second.

Drop-In Is the Oil Trade. Novel Is the Moat

A drop-in bio-chemical, bio-ethylene, bio-MEG, bio-methanol, is by design chemically identical to its fossil twin. That identicality is its strength and its weakness: it slots into existing assets with no downstream change, but it has no moat, because the customer is buying the same molecule with a certificate attached and will switch back the moment the green premium stings. Its margin is set by the gap between a roughly flat bio cost and an oil-linked fossil cost, which means its profitability is an oil bet, profitable above a route-specific crude price and underwater below it. We have mapped that cost curve in detail in our companion piece on drop-in integration; the point here is simply that it is a cost-curve asset, and the oil price is the whole story.

A novel molecule is a different animal. When bio chemistry produces something with a property petroleum-based chemistry cannot easily replicate, the molecule competes on what it does, not on what it costs relative to oil. Polyethylene furanoate, made from bio-based FDCA, has materially better gas-barrier properties than the PET it competes with, which matters for packaging that has to keep oxygen out. Polylactic acid is compostable, a property conventional plastics simply do not have. These are not cheaper petrochemicals; they are better materials, and a better material can hold a price that an identical one never can.

Plot the molecules on performance moat against oil sensitivity and the portfolio logic is immediate. The drop-ins sit in the oil-hostage corner: no moat, high crude sensitivity. The novel molecules sit in the opposite corner: a real property advantage and a premium that survives a crude cycle. They are different asset classes wearing the same “platform chemical” label, and they should never be underwritten the same way.

The Molecules That Earn It

Scored on the four things that actually decide a bio-chemical’s durability, a performance moat, a pulled application, scale-readiness and independence from the oil price, the field separates clearly.

Polylactic acid scores highest, because it pairs a genuine property, compostability, with commercial scale that already exists through producers like NatureWorks and TotalEnergies Corbion, and a PLA market on the order of two billion dollars in 2025 growing at a high-teens rate. PEF and its building block FDCA score nearly as high on the moat, with a smaller but fast-growing FDCA market, but they carry the one risk the moat cannot remove: scale-up. Bio-ethylene, the drop-in, scores low because its value is an oil derivative. And succinic acid sits at the bottom, which is the most instructive result of all.

The Succinic Lesson

A decade ago succinic acid was the poster child of the platform-chemical boom, a molecule on every list of the building blocks that would replace petrochemistry. It did not. The reason is the entire argument of this piece in one cautionary tale: the succinic plants were a cost-curve bet. They were sanctioned when oil traded above a hundred dollars a barrel, on the logic that bio could undercut an expensive fossil incumbent. By the time the plants opened, oil had halved, the fossil incumbent got cheaper, and succinic acid became, in the words of the trade press, an afterthought. BioAmber, the leading producer, went bankrupt in 2018; Reverdia and Myriant exited or retrenched. The chemistry worked. The market thesis, that cost alone was a moat, did not survive contact with a lower oil price.

The more uncomfortable lesson is that even a real moat is not enough on its own. Several venture-backed bioplastics makers with genuinely differentiated, biodegradable chemistry still failed in the last few years, not on the technology but on delays in customer commitments and underutilised capacity. The property was real; the converted demand and the plant utilisation were not. A performance moat is necessary but not sufficient: a novel molecule still dies if the offtake never converts and the plant runs half-empty, the same gap that strands a SAF project. Underwrite the moat, then underwrite whether anyone has actually committed to buy at scale.

That is why the succinic generation stayed tiny while PLA and FDCA are scaling. The survivors are the molecules whose value never rested on the oil price in the first place. The casualty was the one that did. An investor who internalises nothing else from the last bio-chemical cycle should internalise that.

The Demand Has No Mandate

This is the structural difference between platform chemicals and the fuels in the rest of this series, and it is the risk most easily missed. Sustainable aviation fuel and renewable diesel have production mandates: ReFuelEU and the RFS force volume into the market whether buyers feel virtuous or not. A bio-based chemical has no such floor. Its demand is pulled, not pushed, and historically it has been pulled by voluntary corporate sustainability pledges, which is exactly the demand that softens first when the mood turns. The 2025-26 ESG retreat is visible in the language: the share of large US companies using the word ESG in their report titles fell to about a quarter, from forty percent a year earlier. A molecule whose entire business case is a brand’s voluntary green premium is exposed to that retreat in a way a mandated fuel is not.

The nuance, and the part worth underwriting carefully, is that the pull is not disappearing so much as changing source. Beneath the quieter messaging, sustainability spending has held, and the more durable driver is shifting from voluntary pledges to regulation: single-use plastics bans, packaging rules and recycled-content requirements that compel the use of certified materials regardless of how loudly a brand talks about it. Biodegradable-packaging demand is still growing at roughly a fifth a year on that basis. So the question for any platform-chemical investment is which pull it actually depends on. A molecule riding a discretionary brand pledge carries demand risk that looks a lot like the voluntary carbon market; a molecule pulled by a hard regulation, a compostability mandate, a recycled-content rule, has something closer to the mandated demand that makes a fuel bankable. Underwrite the regulation, not the press release about a net-zero commitment.

Where the Crude Spike Fits

This reframes the 2026 oil environment for a chemicals portfolio. A high crude price flatters every drop-in, because it widens the gap between the oil-linked incumbent and the flat bio cost, and that is real money while it lasts. But it is the same flattery that lured the succinic generation to its FID, and crude has already swung from $55 to $120 and back toward the late eighties inside a single year. A drop-in book is long oil whether the investor intends it or not. The novel molecules are close to oil-neutral: PEF’s barrier premium and PLA’s compostability are worth what they are worth regardless of Brent. In a world where crude is this volatile, the performance moat is not only a better margin story; it is a better risk story, the part of the chemicals book that does not move when the oil price does.

What to Watch: Can the Novel Molecule Scale?

The moat is necessary but not sufficient, and the binding question for the novel thesis is execution at scale. Avantium, the clearest pure-play on a novel platform chemical, is the case study in real time. Its FDCA flagship plant, the first of its kind, slipped its schedule after titanium-weld problems raised costs, and is only completing start-up around mid-2026 with first commercial PEF sales in the second half of the year. That is the whole novel-molecule risk in one project: the property advantage is real and the demand is pulling, but a first-of-a-kind plant still has to be built and started without the kind of execution failure that has sunk first-of-a-kind plants in fuels. The inflection to watch across the sector is precisely this transition from validated chemistry and signed brand interest to a plant running at nameplate. The molecules that clear it, and PEF is the nearest test, are genuine PET-scale disruptors. The ones that stall become the next cautionary tale, however good the material.

How We’d Underwrite It

Separate the two asset classes before anything else, and never pay a specialty multiple for a drop-in or an oil-hostage discount for a genuine novel molecule. For a drop-in, underwrite the cost curve and accept that the position is long oil; size it as such. For a novel molecule, underwrite the property first, is the advantage real and valued by a buyer who will pay for it, then the pulled application, then, most carefully, the scale-up. Treat market-size forecasts with suspicion, because the third-party ranges for FDCA and PLA span an order of magnitude and tell you more about the forecaster than the market. And keep the succinic lesson on the desk: a novel label is not a moat, and a molecule whose only case is that it should be cheaper than petroleum is one oil-price move from being an afterthought. The potential in platform chemicals is real, but it is unlocked by the property, not the press release.

What Clears an Investment Committee

1. Classify the molecule first. Drop-in (cost-curve, oil-hostage) or novel (performance moat). They are different assets; do not blend the valuation logic.

2. For a novel molecule, prove the property. A real, buyer-valued advantage petroleum cannot replicate, PEF barrier, PLA compostability, not just lower carbon.

3. Underwrite the scale-up. First-of-a-kind execution is the binding risk; Avantium’s weld delays are the live example. Demand a credible build and start-up plan.

4. Discount the market forecasts. Third-party ranges span an order of magnitude. Underwrite the pulled application you can name, not the TAM.

5. Find the durable demand pull. Chemicals have no production mandate. Prefer a molecule pulled by hard regulation (plastics bans, recycled-content rules) over one riding a voluntary brand pledge that a backlash can soften.

6. Apply the succinic test. If the entire case is “cheaper than the petrochemical,” it is a cost-curve bet that a lower oil price can erase. Pass.

Platform Chemicals: Investor FAQ

What is the difference between drop-in and novel bio-based platform chemicals?

A drop-in (bio-ethylene, bio-MEG, bio-methanol) is chemically identical to its fossil twin, so it slots into existing assets but has no moat and competes purely on cost against an oil-linked incumbent. A novel molecule (PEF/FDCA, PLA) has a property petroleum cannot easily replicate, so it competes on performance and can hold a premium that does not depend on the oil price.

Why is a novel molecule a better investment than a drop-in?

Because its margin is not an oil bet. A drop-in is profitable only above a route-specific crude price and underwater below it, so the position is implicitly long oil. A novel molecule’s premium rests on a functional advantage, PEF’s gas barrier, PLA’s compostability, that is worth what it is worth regardless of where Brent trades, making it both a better margin and a better risk.

What happened to succinic acid and BioAmber?

Succinic acid was a celebrated platform chemical whose plants were sanctioned when oil was above $100 a barrel. By the time they opened oil had halved, the fossil incumbent got cheaper, and succinic became an afterthought. BioAmber, the leading producer, went bankrupt in 2018, and others exited. It is the cautionary tale for any bio-chemical whose only moat is cost.

Is FDCA / PEF a good investment in 2026?

The moat is strong, PEF’s barrier properties give it a genuine performance edge over PET, and the FDCA market is growing. The risk is scale-up: Avantium’s first-of-a-kind FDCA flagship slipped on titanium-weld issues and is only reaching commercial sales in the second half of 2026. The thesis turns on whether the plant runs at nameplate, not on whether the chemistry works.

Does the 2026 crude oil spike help bio-based chemicals?

It helps drop-ins, by widening the gap to the oil-linked fossil incumbent, but that is the same trap that sank the succinic generation when oil later fell. Novel molecules are close to oil-neutral, because their premium is performance-based. In a volatile-crude world the novel molecule is the more durable holding; the drop-in is a long-oil position whether the investor intends it or not.

Do bio-based platform chemicals have a demand mandate like SAF?

No, and that is the key structural risk. Unlike sustainable aviation fuel (ReFuelEU) or renewable diesel (RFS), chemicals have no production mandate; demand is pulled by buyers, not pushed by law. Historically that pull was voluntary corporate sustainability commitments, which soften in an ESG backlash. The more durable pull is regulation, plastics bans, packaging and recycled-content rules, so the safest molecules are the ones a hard rule compels, not the ones a brand pledge merely encourages.

Why do differentiated bioplastics companies still fail?

Because a performance moat is necessary but not sufficient. Several venture-backed bioplastics makers with genuinely differentiated, biodegradable chemistry have failed in recent years, not on the technology but on delays in customer commitments and underutilised capacity. Without converted, contracted demand and a plant running near capacity, even a molecule with a real property advantage can fail, the same demand-conversion gap that strands a SAF project.

Methodology: market sizes are 2025 third-party estimates with wide ranges (PLA ~$1.9 bn, ~17.8% CAGR; FDCA ~$0.9 bn, ~7.8% CAGR; bio-succinic ~$74 m) and should be read as direction, not precision; molecule scores are Trident’s framework. Companies named (Avantium, NatureWorks, TotalEnergies Corbion, BioAmber, Reverdia, Myriant) are illustrative examples, not recommendations. Demand-pull shift per 2025-26 ESG-reporting and bioplastics-regulation analyses. Sources: Avantium disclosures; C&EN (BioAmber, succinic acid); FDCA / PLA / succinic market reports; EU CBE drop-in vs novel framing; ESG and packaging-regulation analyses. Analysis, not investment advice.